Pembrolizumab is an immune checkpoint inhibitor (ICI) that targets the programmed cell death (PD)-1 receptor. It significantly increases the overall survival in patients with locally advanced or metastatic urothelial cancer. However. its administration may induce serious immune-related adverse effects. https://thebanyantreers.shop/product-category/ottoman/